Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov) - Oct 9, 2026 - P2 | N=38 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2026 ➔ Oct 2027
dMMR • Mismatch repair • Trial completion date • Trial primary completion date • Microsatellite Instability • Oncology • Solid Tumor • MSI
|